Moderna 8-K: Board Changes and Executive Compensation
Ticker: MRNA · Form: 8-K · Filed: 2024-07-23T00:00:00.000Z
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: MRNA
TL;DR
Moderna's 8-K shows board shakeup & exec pay details.
AI Summary
On July 19, 2024, Moderna, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the departure of a director and the appointment of a new officer, along with information regarding compensatory arrangements for certain key personnel. The report also covers Regulation FD disclosures and financial statements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation structures can introduce uncertainty and signal potential strategic shifts.
Key Numbers
- 001-38753 — SEC File Number (Moderna's SEC filing identifier)
- 81-3467528 — IRS Employer Identification No. (Moderna's tax identification number)
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- July 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 325 Binney Street, Cambridge, MA 02142 (address) — Principal executive offices
- 617-714-6500 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made to Moderna's board of directors on or around July 19, 2024?
The filing indicates the departure of a director and the election of a new director, though specific names are not detailed in the provided text.
What information is provided regarding executive compensation?
The 8-K report includes details on compensatory arrangements for certain officers.
What other items are covered in this 8-K filing?
The filing also covers Regulation FD disclosures and financial statements and exhibits.
When was Moderna, Inc. incorporated?
Moderna, Inc. was incorporated in Delaware.
What is Moderna's principal executive office address?
Moderna's principal executive office is located at 325 Binney Street, Cambridge, MA 02142.
Filing Stats: 966 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2024-07-23 07:05:39
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
Filing Documents
- mrna-20240719.htm (8-K) — 33KB
- exhibit991-07232024.htm (EX-99.1) — 14KB
- image_0a.jpg (GRAPHIC) — 0KB
- 0001682852-24-000035.txt ( ) — 175KB
- mrna-20240719.xsd (EX-101.SCH) — 2KB
- mrna-20240719_lab.xml (EX-101.LAB) — 21KB
- mrna-20240719_pre.xml (EX-101.PRE) — 12KB
- mrna-20240719_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 23, 2024, the Company issued a press release announcing the appointment of Mr. Rubenstein to the Board and the retirements of Dr. Langer and Mr. Berenson. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated July 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 23, 2024 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer